Silvercrest Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
Other funds holding KNSA
BBA
Silvercrest Asset Management's KNSA Position: Q3 2026 in Review
Silvercrest Asset Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 9.2% in Q3 2026, selling an estimated $745K and leaving 99,244 shares worth $7.4M. The position accounts for 0.05% of the portfolio, ranked #382.
Silvercrest Asset Management first reported a position in KNSA in Q3 2025 and has held it in 5 quarters since. 305 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.
- Silvercrest Asset Management held 99,244 shares of Kiniksa Pharmaceuticals worth $7.4M as of Q3 2026.
- Silvercrest Asset Management sold 10,115 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $745K.
- Kiniksa Pharmaceuticals made up 0.05% of Silvercrest Asset Management's portfolio in Q3 2026, its #382 holding.
- Silvercrest Asset Management first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
- 305 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.
Based on Silvercrest Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.